{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:28Z","timestamp":1782510388195,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,26]],"date-time":"2027-06-26T00:00:00Z","timestamp":1813968000000},"content-version":"am","delay-in-days":329,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.008","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:52:02Z","timestamp":1777499522000},"page":"441-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of High-Risk Non-Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Jacob E.","family":"Tallman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"20","key":"10.1016\/j.ucl.2026.03.008_bib3","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non\u2013muscle-invasive bladder cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.008_bib5","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2021.11.002","article-title":"Somatic features of response and relapse in non\u2013muscle-invasive bladder cancer treated with bacillus calmette-gu\u00e9rin immunotherapy","volume":"5","author":"Bacon","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.008_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/path.4017","article-title":"CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma","volume":"227","author":"Rebouissou","year":"2012","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib8","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.008_bib9","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","article-title":"Prognostic impact of a 12-gene progression score in non\u2013muscle-invasive bladder cancer: a prospective multicentre validation study","volume":"72","author":"Dyrskj\u00f8t","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.clgc.2018.02.001","article-title":"Molecular progression risk score for prediction of muscle invasion in primary T1 high-grade bladder cancer","volume":"16","author":"Kang","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13073-022-01056-4","article-title":"Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes","volume":"14","author":"Goel","year":"2022","journal-title":"Genome Med"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib13","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","article-title":"Clinical\u2013pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base","volume":"88","author":"Gray","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/JU.0000000000001006","article-title":"Utility of routine preoperative 18 F-fluorodeoxyglucose positron emission tomography\/computerized tomography in identifying pathological lymph node metastases at radical cystectomy","volume":"204","author":"Dason","year":"2020","journal-title":"J Urol"},{"issue":"25","key":"10.1016\/j.ucl.2026.03.008_bib15","first-page":"3973","article-title":"Clinical value of fluorine-18 2-Fluoro-2-Deoxy-D-glucose positron emission tomography\/computed tomography in bladder cancer","volume":"28","author":"Apolo","year":"2010","journal-title":"J Clin Orthod"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.008_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2019.09.029","article-title":"Prospective assessment of vesical imaging reporting and data system (VI-RADS) and its clinical impact on the management of high-risk non\u2013muscle-invasive bladder cancer patients candidate for repeated transurethral resection","volume":"77","author":"Del Giudice","year":"2020","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.008_bib18","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.1007\/s00330-019-06117-8","article-title":"Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the vesical imaging-reporting and data system (VI-RADS) at a single reference center","volume":"29","author":"Barchetti","year":"2019","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2001.19.1.89","article-title":"Transurethral resection of muscle-invasive bladder cancer: 10-year outcome","volume":"19","author":"Herr","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000075961","article-title":"Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must Even for experienced urologists","volume":"72","author":"Zurkirchen","year":"2004","journal-title":"Urol Int"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(02)01920-9","article-title":"Impact of a second transurethral resection on the staging of T1 bladder cancer","volume":"60","author":"Dalbagni","year":"2002","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non\u2013muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"issue":"2 Part 1","key":"10.1016\/j.ucl.2026.03.008_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-5347(17)37779-0","article-title":"Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder","volume":"146","author":"Kl\u00e4n","year":"1991","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.eururo.2010.03.007","article-title":"Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial","volume":"58","author":"Divrik","year":"2010","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib25","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1464-410X.2006.06145.x","article-title":"A re-staging transurethral resection predicts early progression of superficial bladder cancer","volume":"97","author":"Herr","year":"2006","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib26","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euo.2024.10.004","article-title":"En Bloc versus conventional transurethral resection of bladder tumors: a systematic review and meta-analysis of oncological, histopathological, and surgical outcomes","volume":"8","author":"Basile","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.euo.2023.07.010","article-title":"En Bloc versus conventional resection of primary bladder tumor (eBLOC): a prospective, multicenter, open-label, phase 3 randomized controlled Trial","volume":"6","author":"D\u2019Andrea","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.euo.2022.05.001","article-title":"En Bloc versus conventional transurethral resection of bladder tumors: a single-center prospective randomized noninferiority trial","volume":"5","author":"Gallioli","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.eururo.2024.04.015","article-title":"Transurethral En Bloc resection versus standard resection of bladder tumour: a randomised, multicentre, phase 3 trial","volume":"86","author":"Teoh","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib30","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.euf.2020.12.003","article-title":"Holmium laser En-bloc resection versus conventional transurethral resection of bladder tumors for treatment of non-muscle-invasive bladder cancer: a randomized clinical trial","volume":"7","author":"Hashem","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bju.15150","article-title":"Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non-muscle-invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trial","volume":"126","author":"Gakis","year":"2020","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000472824","article-title":"Radical cystectomy - often too late?","volume":"13","author":"St\u00f6ckle","year":"1987","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.008_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3)","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1464-410X.2012.11391.x","article-title":"Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection","volume":"112","author":"Sternberg","year":"2013","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus calmette-guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1078-1439(00)00099-5","article-title":"Bacillus calmette-guerin","volume":"6","author":"Flanigan","year":"2001","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23627","article-title":"Maintenance bacillus calmette-gu\u00e9rin in high-risk nonmuscle-invasive bladder cancer: how much is enough?","volume":"113","author":"Decobert","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus calmette-gu\u00e9rin is superior to a combination of epirubicin and interferon-\u03b12b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.008_bib44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus calmette-gu\u00e9rin instillation for Ta, T1 cancer and carcinoma In Situ of the bladder: randomized controlled trial by the BCG Tokyo strain study group","volume":"17","author":"Koga","year":"2010","journal-title":"Int J of Urology"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus calmette-gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non\u2013muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib46","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/UA.UA_137_19","article-title":"Single course of intravesical bacillus calmette\u2013guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: a prospective randomized study","volume":"12","author":"Ali","year":"2020","journal-title":"Urol Ann"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.008_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/11795549231184682","article-title":"Evaluating the effectiveness of intravesical instillation of BCG by modified maintenance method in patients with high-risk Ta and T1 bladder cancer: a randomized clinical trial","volume":"17","author":"Shakhssalim","year":"2023","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/03915603231206603","article-title":"Comparative study between mitomycin C versus bacillus calmette-gu\u00e9rin (BCG) in high-risk non-muscle-invasive bladder cancer","volume":"91","author":"Zaza","year":"2024","journal-title":"Urologia"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib50","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus calmette-gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus calmette-gu\u00e9rin\u2012na\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.008_bib52","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"7_suppl","key":"10.1016\/j.ucl.2026.03.008_bib53","first-page":"TPS500","article-title":"A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)","volume":"37","author":"De Santis","year":"2019","journal-title":"J Clin Orthod"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2026.03.008_bib55","first-page":"TPS4589","article-title":"ALBAN: an open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus calmette-guerin) bladder instillation in BCG-Naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37)","volume":"37","author":"Roupret","year":"2019","journal-title":"J Clin Orthod"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib56","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib57","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with Mitomycin C versus bacillus calmette-gu\u00e9rin for adjuvant treatment of patients with Intermediate- and high-risk Non\u2013muscle-Invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.03.008_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euros.2024.01.013","article-title":"The safety, tolerability, and preliminary efficacy of a gemcitabine-releasing intravesical system (TAR-200) in American urological association\u2013defined intermediate-risk non\u2013muscle-invasive bladder cancer patients: a phase 1b study","volume":"62","author":"Van Valenberg FJ","year":"2024","journal-title":"European Urology Open Science"},{"issue":"7\u20138","key":"10.1016\/j.ucl.2026.03.008_bib60","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0264-410X(98)00277-1","article-title":"A historical and molecular phylogeny of BCG strains","volume":"17","author":"Behr","year":"1999","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib61","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and update for S1602 \u201cA phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-Na\u00efve high-grade non-muscle-invasive bladder cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"European Urology Focus"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and drug administration and American urological association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2026.03.008_bib63","first-page":"1","article-title":"BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. Silver spring, MD: U.S. department of health and human services","year":"2018","journal-title":"Food and Drug Administration"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.008_bib64","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.008_bib65","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of pembrolizumab for bacillus calmette-gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib66","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus calmette-gu\u00e9rin\u2013unresponsive high-risk non\u2013muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib67","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive Non\u2013muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib68","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib69","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus calmette-Gu\u00e9rin\u2013Unresponsive nonmuscle-invasive bladder cancer: 5-year Follow-Up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J Urol"},{"issue":"5S2","key":"10.1016\/j.ucl.2026.03.008_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001015816.87470.c9.02","article-title":"P2-02 pivotal results from BOND-003: a phase 3, single-arm study of intravesical CRETOSTIMOGENE GRENADENOREPVEC for the treatment of high risk, BCG-unresponsive NON-muscle invasive bladder cancer with carcinoma in situ","volume":"211","author":"Tyson","year":"2024","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.03.008_bib71","first-page":"2729","article-title":"Phase II trial of intravesical gemcitabine in bacille calmette-Gu\u00e9rin\u2013Refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2009.06.112","article-title":"Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non\u2013muscle-invasive bladder cancer refractory to standard intravesical therapy","volume":"75","author":"Laudano","year":"2010","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib73","doi-asserted-by":"crossref","first-page":"35.e15-e19","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non\u2013muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.008_bib74","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.03.008_bib75","first-page":"TPS579","article-title":"A phase II trial of intravesical chemoimmunotherapy with gemcitabine and bacillus calmette-gu\u00e9rin (BCG) for patients with BCG-exposed, high-grade, non-muscle\u2013invasive bladder cancer","volume":"41","author":"Gaffney","year":"2023","journal-title":"J Clin Orthod"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.008_bib76","doi-asserted-by":"crossref","first-page":"850.e9-e15","DOI":"10.1016\/j.urolonc.2020.06.031","article-title":"Sequential administration of bacillus calmette-guerin (BCG) and electromotive drug administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure","volume":"38","author":"Juvet","year":"2020","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.008_bib77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.ucl.2026.03.008_bib79","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.008_bib80","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-Treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.008_bib82","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus calmette-guerin refractory carcinoma in situ of the bladder. The valrubicin study group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.008_bib83","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus calmette-gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib84","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus calmette-guerin (BCG) or external beam radiation therapy in patients with BCG-Unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.008_bib87","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2021.03.024","article-title":"Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG","volume":"40","author":"Steinberg","year":"2022","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib88","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with bacillus calmette-gu\u00e9rin in patients with bacillus calmette-Gu\u00e9rin\u2013Unresponsive non\u2013muscle invasive bladder cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.008_bib89","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk Non-Muscle-Invasive bladder cancer: eurogemdoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.008_bib90","first-page":"33","article-title":"Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC","volume":"18","author":"Garneau","year":"2024","journal-title":"Can Urol Assoc J"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2026.03.008_bib91","first-page":"TPS593","article-title":"SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to bacillus calmette-gu\u00e9rin who are ineligible for or decline radical cystectomy","volume":"40","author":"Van Der Heijden","year":"2022","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ucl.2026.03.008_bib92","article-title":"2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus calmette-gu\u00e9rin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.008_bib93","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","article-title":"Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial","volume":"30","author":"Li","year":"2024","journal-title":"Nat Med"},{"issue":"Supplement 4","key":"10.1016\/j.ucl.2026.03.008_bib94","article-title":"PD03-02 phase 3 results of VICINIUM in BCG-unresponsive NON-muscle invasive bladder cancer","volume":"203","author":"Shore","year":"2020","journal-title":"J Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:56:01Z","timestamp":1782507361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000340"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.008","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of High-Risk Non-Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}